{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:07:15Z","timestamp":1762506435256},"reference-count":45,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journals.elsevierhealth.com","europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.eururo.2014.08.076","type":"journal-article","created":{"date-parts":[[2014,9,11]],"date-time":"2014-09-11T01:03:16Z","timestamp":1410397396000},"page":"904-912","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Achievements and Perspectives in Prostate Cancer Phase 3 Trials from Genitourinary Research Groups in Europe: Introducing the Prostate Cancer Consortium in Europe"],"prefix":"10.1016","volume":"67","author":[{"given":"Karim","family":"Fizazi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per-Anders","family":"Abrahamsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Goran","family":"Ahlgren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaquim","family":"Bellmunt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephane","family":"Culine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"de Wit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silke","family":"Gillessen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juergen E.","family":"Gschwend","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Freddie","family":"Hamdy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"James","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kurt","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Wiegel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfred","family":"Wirth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertrand","family":"Tombal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2014.08.076_bib0005","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","article-title":"Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012","volume":"49","author":"Ferlay","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2014.08.076_bib0010","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.eururo.2012.02.054","article-title":"International variation in prostate cancer incidence and mortality rates","volume":"61","author":"Center","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.08.076_bib0015","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1093\/annonc\/mds624","article-title":"Prostate cancer: ESMO Consensus Conference guidelines 2012","volume":"24","author":"Horwich","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2014.08.076_bib0020","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1113135","article-title":"Prostate-cancer mortality at 11 years of follow-up","volume":"366","author":"Schr\u00f6der","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2014.08.076_bib0025","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(10)70223-0","article-title":"External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study","volume":"11","author":"Bolla","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2014.08.076_bib0030","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1056\/NEJMoa0810095","article-title":"Duration of androgen suppression in the treatment of prostate cancer","volume":"360","author":"Bolla","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2014.08.076_bib0035","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(08)61815-2","article-title":"Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7\/SFUO-3): an open randomised phase III trial","volume":"373","author":"Widmark","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2014.08.076_bib0040","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1200\/JCO.2008.18.9563","article-title":"Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02\/AUO AP 09\/95","volume":"27","author":"Wiegel","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.08.076_bib0045","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(12)61253-7","article-title":"Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)","volume":"380","author":"Bolla","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2014.08.076_bib0050","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa1011967","article-title":"Radical prostatectomy versus watchful waiting in early prostate cancer","volume":"364","author":"Bill-Axelson","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2014.08.076_bib0055","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1001\/jama.2011.1437","article-title":"Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)","volume":"306","author":"Klein","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2014.08.076_bib0060","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.1996.14.6.1756","article-title":"Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points","volume":"14","author":"Tannock","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.08.076_bib0065","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1201546","article-title":"Intermittent androgen suppression for rising PSA level after radiotherapy","volume":"367","author":"Crook","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2014.08.076_bib0070","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1016\/S0140-6736(11)61095-7","article-title":"Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial","volume":"378","author":"Warde","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2014.08.076_bib0075","first-page":"111","article-title":"Lessons from phase III-trials on the hormonal treatment of prostatic cancer. I: Results of EORTC-trials 30761 and 30762","volume":"260","author":"de Voogt","year":"1988","journal-title":"Prog Clin Biol Res"},{"key":"10.1016\/j.eururo.2014.08.076_bib0080","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1159\/000475067","volume":"28","author":"Robinson","year":"1995","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.08.076_bib0085","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000019546","article-title":"Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center","volume":"33","author":"Denis","year":"1998","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.08.076_bib0090","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000019547","volume":"33","author":"de Voogt","year":"1998","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.08.076_bib0095","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.eururo.2003.11.016","article-title":"Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the \u201cEuropean Organization for Research and Treatment of Cancer\u201d (EORTC) Protocol 30892","volume":"45","author":"Schroder","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.08.076_bib0100","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1159\/000020191","article-title":"Quality of life of patients with newly diagnosed poor prognosis M1 prostate cancer undergoing orchiectomy without or with mitomycin C. Results from the EORTC Phase-III trial 30893","volume":"37","author":"Fossa","year":"2000","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.08.076_bib0105","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1200\/JCO.2005.04.7423","article-title":"Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891","volume":"24","author":"Studer","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.08.076_bib0110","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.eururo.2007.12.032","article-title":"Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891)","volume":"53","author":"Studer","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.08.076_bib0115","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.eururo.2008.09.008","volume":"55","author":"Schroder","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.08.076_bib0120","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3109\/00365599709070324","article-title":"Treatment of high-grade, high-stage prostate cancer with estramustine phosphate or diethylstilbestrol. A double-blind study. The SPCG-1 Study Group. Scandinavian Prostate Cancer Group","volume":"31","author":"Hedlund","year":"1997","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.eururo.2014.08.076_bib0125","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1159\/000474351","article-title":"Total androgen suppression: experience from the Scandinavian Prostatic Cancer Group Study No. 2","volume":"24","author":"J\u00f8rgensen","year":"1993","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.08.076_bib0130","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/003655902762467549","article-title":"Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer--Scandinavian Prostatic Cancer Group (SPCG) study no. 5","volume":"36","author":"Hedlund","year":"2002","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.eururo.2014.08.076_bib0135","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1080\/00365590601017329","article-title":"Bicalutamide 150mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 study after a median follow-up period of 7.1 years","volume":"40","author":"Iversen","year":"2006","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.eururo.2014.08.076_bib0140","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.eururo.2014.02.014","article-title":"Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS)","volume":"67","author":"Wirth","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.08.076_bib0145","doi-asserted-by":"crossref","first-page":"5366","DOI":"10.1200\/JCO.2006.10.5171","article-title":"Is there a role for pelvic irradiation in localized prostate adenocarcinoma. Preliminary results of GETUG-01","volume":"25","author":"Pommier","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.08.076_bib0150","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.ijrobp.2010.03.049","article-title":"70Gy vs 80Gy in localized prostate cancer: 5-year results of GETUG 06 randomised trial","volume":"80","author":"Beckendorf","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2014.08.076_bib0155","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ejca.2011.10.015","article-title":"A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial","volume":"48","author":"Fizazi","year":"2012","journal-title":"Eur J Cancer"},{"issue":"Suppl","key":"10.1016\/j.eururo.2014.08.076_bib0160","article-title":"Does short-term androgen depletion add to high-dose radiotherapy (80Gy) in localized intermediate-risk prostate cancer\u2014intermediary analysis of GETUG 14 randomized trial (EU-20503\/NCT00104741) [abstract 4521]","volume":"29","author":"Dubray","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.08.076_bib0165","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","article-title":"Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial","volume":"14","author":"Gravis","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2014.08.076_bib0170","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1470-2045(07)70143-2","article-title":"Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial","volume":"8","author":"Dearnaley","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2014.08.076_bib0175","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/jnci\/djk178","article-title":"Oral sodium clodronate for nonmetastatic prostate cancer--results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873)","volume":"99","author":"Mason","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2014.08.076_bib0180","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1470-2045(09)70201-3","article-title":"Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials","volume":"10","author":"Dearnaley","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2014.08.076_bib0185","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1470-2045(12)70088-8","article-title":"Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial","volume":"13","author":"James","year":"2012","journal-title":"Lancet Oncol"},{"issue":"Suppl","key":"10.1016\/j.eururo.2014.08.076_bib0190","volume":"31","author":"James","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.08.076_bib0195","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.eururo.2013.03.029","article-title":"Phase 3 study of adjuvant radiotherapy versus wait and see in pT3 prostate cancer: impact of pathology review on analysis","volume":"64","author":"Bottke","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.08.076_bib0230","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2014.03.011","article-title":"Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10 year follow-up of the ARO 96-02\/AUO AP 09\/95 trial","volume":"66","author":"Wiegel","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.08.076_bib0205","first-page":"238s","article-title":"Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer [abstract 5015]","volume":"25","author":"Miller","year":"2007","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.eururo.2014.08.076_bib0210","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1016\/j.ejca.2012.05.014","article-title":"Randomised phase II\/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro)","volume":"48","author":"Meulenbeld","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2014.08.076_bib0215","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/annonc\/mdq404","article-title":"Predictors of state-of-the-art management of early breast cancer in Switzerland","volume":"22","author":"Ess","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2014.08.076_bib0220","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1634\/theoncologist.2012-0327","article-title":"Emphasising the European Union's Commitment to Cancer Research: a helicopter view of the Seventh Framework Programme for Research and Technological Development","volume":"17","author":"van de Loo","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.eururo.2014.08.076_bib0225","unstructured":"Horizon 2020: Support for researchers in Switzerland. Swiss Federal Administration News Web site. https:\/\/www.news.admin.ch\/message\/index.html?lang=en&msg-id=53516."}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228381400880X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228381400880X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T21:52:36Z","timestamp":1565819556000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030228381400880X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S030228381400880X"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2014.08.076","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Achievements and Perspectives in Prostate Cancer Phase 3 Trials from Genitourinary Research Groups in Europe: Introducing the Prostate Cancer Consortium in Europe","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2014.08.076","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}